IP Library › Granted Patent US 12,589,082
Granted Patent B2
US 12,589,082 · App. 17/425,483 · Granted Mar 31, 2026

Compositions comprising thymoquinone and additional biologically active compounds

Inventors: Mor Zeilkha (Ramat Gan, IL); Dan Rapaport (Kfar Haroe'e, IL)
Assignee: N.S. OILS LTD.
A61K31/122A61K31/015A61K31/353A61K31/658A61K36/3482
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,589,082
App. No.
17/425,483
Granted
Mar 31, 2026
Kind
B2
Abstract

The present invention is directed to a composition comprising a combination of thymoquinone (TQ) and one or more additional biologically active agents, wherein said biologically active agents are selected from the group consisting of carotenoids, Cannabis -related compounds and pycnogenol. In one preferred embodiment, the TQ is contained in cold-pressed Nigella sativa oil, wherein said oil is characterized by a TQ concentration of at least 1.5% (w/w) and a free fatty acid (FFA) content of 3.5% (w/w) or less. The present invention is also directed to methods for treating or preventing inflammatory conditions by means of administering these compositions.

Claims (13)

1 . A composition comprising a combination of thymoquinone (TQ) and astaxanthin, wherein the weight ratio of said TQ to said astaxanthin is in the range of 1:1 to 1:200, wherein the composition is characterized by synergism between said TQ and said astaxanthin with respect to their inhibition of nitric oxide production, and wherein said TQ is present in a cold-pressed oil obtained from Nigella sativa seeds.

2 . The composition according to claim 1 , further including one or more cannabinoids.

3 . The composition according to claim 2 , wherein the cannabinoid is cannabidiol (CBD).

4 . The composition according to claim 3 , wherein the CBD is contained in a hemp extract.

5 . The composition according to claim 1 , further including pycnogenol.

6 . The composition according to claim 1 , wherein the concentration of TQ is at least 1.5% (w/w), and wherein the composition further comprises free fatty acids (FFA) at a concentration of not more than 3.5% (w/w).

7 . The composition according to claim 1 , wherein the concentration of TQ is at least 1.5% (w/w).

8 . The composition according to claim 7 , wherein the concentration of TQ is at least 2% (w/w).

9 . The composition according to claim 1 , wherein said composition further comprises free fatty acids (FFA) at a concentration of not more than 3.5% (w/w).

10 . The composition according to claim 9 , wherein the weight ratio of FFA to TQ is equal to or less than 2.33:1.

11 . The composition according to claim 10 , wherein the weight ratio of FFA to TQ is equal to or less than 1:1.

12 . The composition according to claim 1 , wherein the concentration of said TQ in said composition is at least 1.5% (w/w), and wherein said composition further comprises FFA at a concentration of no more than 3.5% (w/w).

13 . A method for inhibiting nitric oxide production in a subject, comprising administering to the subject an effective amount of a composition according to claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2025
From: ZEILKHA, MOR; RAPAPORT, DAN
To: N.S. OILS LTD.
Reel/Frame 071316/0782 →
Continuity (2)
Provisional Application 62797394 · Jan 28, 2019
Related Publication 20220087953A1 · Mar 24, 2022
References Cited (18)
US 11426365B2 · Sela · 2022 [cited by examiner]
US 11883455B2 · Albert · 2024 [cited by examiner]
US 20180125914A1 · Madhavamenon · 2018 [cited by examiner]
DE 202005007603U1 · 2005 [cited by examiner]
WO WO2019016794A1 · 2019 [cited by examiner]
WO WO2019180719A1 · 2019 [cited by examiner]
George, B. and Kumaran, B. “Protective effect of Nigella sativa oil and Astaxanthin on Monosodium glutamate Induced dyslipidemia in Rats”, Int. Arch. App. Sci. Technol., vol. 6, Dec. 2015, p. 1-7. (Year: 2015). [cited by examiner]
Machine translation for DE202005007603U1. Espacenet, Accessed Sep. 2024, p. 1-15. (Year: 2005). [cited by examiner]
Amin, Bahareh, and Hossein Hosseinzadeh. “Black Cumin ( [cited by examiner]
Mohammed, Nameer Khairullah, et al. “The Effects of Different Extraction Methods on Antioxidant Properties, Chemical Composition, and Thermal Behavior of Black Seed ( [cited by examiner]
Semiha Dede et al: “In vitro Evaluation of Thymoquinone and Lycopene Supplementation on Oxidative DNA Damage and Oxidant Status in High Glucose Conditions”, Latin American Journal of Pharmacy, Jan. 1, 2019, pp. 2383-236… [cited by applicant]
Binu George et al: “Protective effect of Nigella sativa oil and Astaxanthin on Monosodium glutamate Induced dyslipidemia in Rats”, International Archive of Applied Sicences and Technology, Dec. 1, 2015, pp. 1-7. DOI: 10… [cited by applicant]
Said Gharby et al: “Chemical investigation of [cited by applicant]
Khan Ma: “Chemical composition and medicinal properties of Nigella sativa Linn.”, Inflammopharmacology, vol. 7, Mar. 1999, pp. 15-35. DO: 10.1007/s10787-999-0023-y. [cited by applicant]
Feakes J.: “Health Benefits of Cannabis and Black Seed Oil”, retrieved from the internet at URL <https://greendorphin.com/benefits-of-cannabis-and-black-seed-oil/>, (retrieved on Dec. 31, 2024), Dec. 10, 2018. [cited by applicant]
Gonzalez M. et al.: “Barrington and TriNutra help launch blend of ThymoQuin and Pycnogenol”, retrieved from the internet at URL:<https://nutraceuticalbusinessreview.com/barrington-and-trinutra-help-launch-blend-ofthymoq… [cited by applicant]
Burstein S.: “Cannabidiol (CBD) and its analogs: a review of their effects on inflammation”, Bioorg. Med. Chem. 23(7):pp. 1377-1385 (2015). [cited by applicant]
Peng Y-J: “Pycnogenol attenuates the inflammatory and nitrosative stress on joint inflammation induced by urate crystals”, Free Radic. Biol. Med. 52(4) :pp. 765-774 (2011). [cited by applicant]